

WHO Position Paper on Measles Vaccines, Aug 2009

References

Epidemiology

WHO: Progress in global measles control and mortality reduction, 2000–2007. *Wkly Epidemiol Rec* 2008; 83, 441–448.

WHO: Measles global annual reported incidence and MCV coverage, 1980-2003. <http://www.who.int/vaccines-surveillance/graphics/htmls/IncMeas.htm> (last accessed 10 January 2006).

Enquselassie F, Ayele W, Dejene A, Messele T, Abebe A, Cutts FT, Nokes DJ. Seroepidemiology of measles in Addis Ababa, Ethiopia: implications for control through vaccination. *Epidemiol Infect.* 2003 Jun;130(3):507-19.

Samb B, Aaby P, Whittle HC, Seck AM, Rahman S, Bennett J, Markowitz L, Simondon F. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. *Pediatr Infect Dis J.* 1995 Mar;14(3):203-9.

Campbell C, Levin S, Humphreys P, Walop W, Brannan R. Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. *BMC Pediatr.* 2005 Dec 15;5:47.

Measles viruses

Rota PA, Featherstone DA, Bellini WJ. Molecular epidemiology of measles virus. *Curr Top Microbiol Immunol.* 2009;330:129-50.

Schneider-Schaulies S, Schneider-Schaulies J. Measles virus-induced immunosuppression. *Curr Top Microbiol Immunol.* 2009;330:243-69.

Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. *Vaccine.* 2008 Apr 16;26(17):2111-8.

Okafuji T, Okafuji T, Fujino M, Nakayama T. Current status of measles in Japan: molecular and seroepidemiological studies. *J Infect Chemother.* 2006 Dec;12(6):343-8.

Measles disease

Griffin DE, Oldstone MM. Measles. Pathogenesis and control. Introduction. *Curr Top Microbiol Immunol.* 2009;330:1 (No summary)

Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. *Int J Epidemiol.* 2009 Feb;38(1):192-205.

Nandy R, Handzel T, Zaneidou M, Biey J, Cuddy RZ, Perry R, Strebel P, Cairns L. Case-fatality rate during a measles outbreak in eastern Niger in 2003. *Clin Infect Dis.* 2006 Feb 1;42(3):322-8.

Perry RT, Halsey NA. The clinical significance of measles: a review. *J Infect Dis.* 2004 May 1;189 Suppl 1:S4-16.

Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. *Cochrane Database Syst Rev.* 2005 Oct 19;(4):CD001479.

Glasziou PP, Mackerras DE. Vitamin A supplementation in infectious diseases: a meta-analysis. *BMJ.* 1993 Feb 6;306(6874):366-70.

Measles vaccines

Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, eds. *Vaccines.* 4th ed. Philadelphia, Pa: Elsevier Inc; 2004:406-407.

WHO/UNICEF measles vaccination coverage information:
<http://www.who.int/vaccines-surveillance/graphics/htmls/IncMeas.htm>

Immunogenicity

Saffar MJ, Ajami A, Khalilian AR, Saffar H. The impact of maternal measles-rubella-immunization on the 12-month-old infant's immune response to measles-mumps-rubellavaccine immunogenicity. *Eur J Clin Microbiol Infect Dis.* 2009 Jul;28(7):845-7.

Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and

a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. *BMC Med.* 2009 Apr 14;7:16.

Kurubi J, Vince J, Ripa P, Tefuarani N, Riddell M, Duke T. Immune response to measles vaccine in 6 month old infants in Papua New Guinea. *Trop Med Int Health.* 2009 Feb;14(2):167-73.

Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. *Vaccine.* 2009 Jan 14;27(3):446-53.

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. *Pediatr Infect Dis J.* 2008 Aug;27(8):724-30.

Dhillon S, Curran MP. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). *Paediatr Drugs.* 2008;10(5):337-47.

Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. *Infection.* 2007 Oct;35(5):326-33.

Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, Beckers F, Descamps D, Willems P. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. *Eur J Pediatr.* 2007 Aug;166(8):857-64.

Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. *Pediatr Infect Dis J.* 2007 Feb;26(2):153-8.

Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatr Infect Dis J.* 2006 Apr;25(4):306-11.

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. *Pediatr Infect Dis J.* 2005 Dec;24(12):1083-8.

John S, Lalitha G, George K, Joseph A. Serological response to early measles vaccination. *J Trop Pediatr.* 2004 Jun;50(3):175-7.

Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. *Expert Opin Pharmacother.* 2003 Aug;4(8):1215-25.

Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, Souza VA. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. *Clin Diagn Lab Immunol.* 2004 Jan;11(1):119-22.

Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. *Asian Pac J Allergy Immunol.* 2002 Jun;20(2):113-20.

Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, Salmi A, Peltola H. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. *Epidemiol Infect.* 2000 Apr;124(2):263-71.

Pannuti CS, Moraes JC, Souza VA, Camargo MC, Hidalgo NT. Measles antibody prevalence after mass immunization in São Paulo, Brazil. *Bull World Health Organ.* 1991;69(5):557-60.

Efficacy-Effectiveness

Sheppard V, Forssman B, Ferson MJ, Moreira C, Campbell-Lloyd S, Dwyer DE, McAnulty JM. Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. *Commun Dis Intell.* 2009 Mar;33(1):21-6.

Velicko I, Müller LL, Pebody R, Gergonne B, Aidyralieva C, Kostiuhenko N, Spika JS. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. *Vaccine.* 2008 Dec 9;26(52):6980-5.

Wichmann O, Hellenbrand W, Sagebiel D, Santibanez S, Ahlemeyer G, Vogt G, Siedler A, van Treeck U. Large measles outbreak at a German public school, 2006. *Pediatr Infect Dis J*. 2007 Sep;26(9):782-6.

Elliman D, Sengupta N, El Bashir H, and Bedford H. Child health. Measles, mumps, and rubella prevention. *Clinical Evidence*. Web publication date: 01 Feb 2007. http://clinicalevidence.bmj.com/ceweb/conditions/chd/0316/0316_II.jsp

Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees—a longitudinal study. *Vaccine*. 2006 Mar 24;24(14):2594-601.

Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. *Clin Infect Dis*. 2006 Feb 1;42(3):315-9.

Yeung LF, Lurie P, Dayan G, Eduardo E, Britz PH, Redd SB, Papania MJ, Seward JF. A limited measles outbreak in a highly vaccinated US boarding school. *Pediatrics*. 2005 Dec;116(6):1287-91.

Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev*. 2005 Oct 19;(4): CD004407.

Borus PK, Cumberland P, Sonoiya S, Kombich J, Tukei PM, Cutts FT. Measles trends and vaccine effectiveness in Nairobi, Kenya. *East Afr Med J*. 2003 Jul;80(7):361-4.

Akramuzzaman SM, Cutts FT, Hossain MJ, Wahedi OK, Nahar N, Islam D, Shaha NC, Mahalanabis D. Measles vaccine effectiveness and risk factors for measles in Dhaka, Bangladesh. *Bull World Health Organ*. 2002;80(10):776-82.

Hennessey KA, Ion-Nedelcu N, Craciun MD, Toma F, Wattigney W, Strebel PM. Measles epidemic in Romania, 1996-1998: assessment of vaccine effectiveness by case-control and cohort studies. *Am J Epidemiol*. 1999 Dec 1;150(11):1250-7.

Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. *Lancet*. 1999;353:98-101.

Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. *Am J Epidemiol*. 1999;150:1238-1249.

Lee MS, Lee LL, Chen HY, Wu YC, Horng CB. Post mass-immunization measles outbreak in Taoyuan County, Taiwan: dynamics of transmission, vaccine effectiveness, and herd immunity. *Int J Infect Dis.* 1998-1999 Winter;3(2):64-9.

Sutcliffe PA, Rea E. Outbreak of measles in a highly vaccinated secondary school population. *CMAJ.* 1996 Nov 15;155(10):1407-13.

Kaninda AV, Legros D, Jataou IM, Malfait P, Maisonneuve M, Paquet C, Moren A. Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995. *Pediatr Infect Dis J.* 1998 Nov;17(11):1034-9.

Singh J, Datta KK. Measles vaccine efficacy in India: a review. *J Commun Dis.* 1997 Mar;29(1):47-56.

Güriş D, McCready J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. *Pediatr Infect Dis J.* 1996 Dec;15(12):1082-6.

Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. *BMJ.* 1995 Aug 19;311(7003):481-5

Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. *N Engl J Med.* 1994 Nov 24;331(21):1397-402

Herceg A, Passaris I, Mead C. An outbreak of measles in a highly immunised population: immunisation status and vaccine efficacy. *Aust J Public Health.* 1994 Sep;18(3):249-52.

Yuan L. Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. *CMAJ.* 1994 Apr 1;150(7):1093-8.

Malfait P, Jataou IM, Jollet MC, Margot A, De Benoist AC, Moren A. Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. *Pediatr Infect Dis J.* 1994 Jan;13(1):38-45.

Hersh BS, Markowitz LE, Hoffman RE, Hoff DR, Doran MJ, Fleishman JC, Preblud SR, Orenstein WA. A measles outbreak at a college with a prematriculation immunization requirement. *Am J Public Health.* 1991 Mar;81(3):360-4.

Koenig MA, Khan MA, Wojtyniak B, Clemens JD, Chakraborty J, Fauveau V, Phillips JF, Akbar J, Barua US. Impact of measles vaccination on childhood mortality in rural Bangladesh. *Bull World Health Organ.* 1990;68(4):441-7.

Anonymous. Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the medical research council by the measles vaccines committee. *BMJ* 1968;2:449-452.

Marin M, Nguyen HQ, Langidrik JR, Edwards R, Briand K, Papania MJ, Seward JF, LeBaron CW. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy. *Clin Infect Dis.* 2006 Feb 1;42(3):315-9. Miller C. Live measles vaccine: a 21 year follow up. *Br Med J (Clin Res Ed).* 1987 Jul 4;295(6589):22-4.

Duration of protection/persistence of antibodies

Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. *Vaccine.* 2008 Apr 16;26(17):2111-8.

Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *J Infect Dis.* 2008 Apr 1;197(7):950-6.

LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S, Gargiullo P. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. *Arch Pediatr Adolesc Med.* 2007 Mar;161(3):294-301.

Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccines—a longitudinal study. *Vaccine.* 2006;24: 2594-2601.

Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. *J Infect Dis.* 2004 May 1;189 Suppl 1:S123-30.

Hirose M, Hidaka Y, Miyazaki C, Ueda K, Yoshikawa H. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination. *Scand J Infect Dis.* 1997;29(2):187-90.

Güriş D, McCreedy J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. *Pediatr Infect Dis J.* 1996 Dec;15(12):1082-6.

Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC. Secondary failure rates of measles vaccines: a metaanalysis of published studies. *Pediatr Infect Dis J.* 1996 Jan;15(1):62-6.

Ramsay ME, Moffatt D, O'Connor M. Measles vaccine: a 27-year follow-up. *Epidemiol Infect.* 1994 Apr;112(2):409-12.

Hersh BS, Markowitz LE, Hoffman RE, Hoff DR, Doran MJ, Fleishman JC, Preblud SR, Orenstein WA. A measles outbreak at a college with a prematriculation immunization requirement. *Am J Public Health.* 1991 Mar;81(3):360-4.

Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF. A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. *Am J Epidemiol.* 1990 Jul;132(1):157-68.

Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles vaccine-induced immunity. *Pediatr Infect Dis J.* 1990;9:101-110.

Mathias RG, Meekison WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. *Am J Public Health.* 1989 Apr;79(4):475-8.

Miller C. Live measles vaccine: a 21 year follow up. *Br Med J (Clin Res Ed).* 1987 Jul 4;295(6589):22-4.

Nkowane BM, Bart SW, Orenstein WA, Baltier M. Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. *Am J Public Health.* 1987 Apr;77(4):434-8.

Faust HS, Thompson FE. Age at and time since vaccination during a measles outbreak in a rural community. *Am J Dis Child.* 1983 Oct;137(10):977-80.

One versus two doses

Lynn TV, Beller M, Funk EA, Middaugh JP, Ritter D, Rota PA, Bellini WJ, Torok TJ. Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak. *J Infect Dis.* 2004 May 1;189 Suppl 1:S86-90.

Thomas A, Xu D, Wooten K, Morrow B, Redd S. Timing and effectiveness of requirements for a second dose of measles vaccine. *Pediatr Infect Dis J.* 1999 Mar;18(3):266-70.

Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. *Vaccine.* 1998 Dec;16(20):2052-7.

Bartoloni A, Cutts FT, Guglielmetti P; et al. Response to measles revaccination among Bolivian school-aged children. *Trans R Soc Trop Med Hyg.* 1997;91:716-718.

Poland GA, Jacobson RM, Thampy AM, Colbourne SA, Wollan PC, Lipsky JJ, Jacobsen SJ. Measles reimmunization in children seronegative after initial immunization. *JAMA.* 1997 Apr 9;277(14):1156-8

Cohn ML, Robinson ED, Faerber M; et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. *Pediatr Infect Dis J.* 1994;13:34-38.

Ozanne G, d'Halewyn MA. Secondary immune response in a vaccinated population during a large measles epidemic. *J Clin Microbiol.* 1992 Jul;30(7):1778-82

HIV and measles vaccination

WHO: Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. *Wkly Epidemiol Rec.* 2009; 84, 325-332.

Lowther SA, Curriero FC, Kalish BT, Shields TM, Monze M, Moss WJ. Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey. *Lancet.* 2009 Mar 21;373(9668):1025-32.

Helfand RF, Witte D, Fowlkes A, Garcia P, Yang C, Fudzulani R, Walls L, Bae S, Strebel P, Broadhead R, Bellini WJ, Cutts F. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. *J Infect Dis.* 2008 Nov 15;198(10):1457-65

Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. *Int J Epidemiol*. 2008 Apr;37(2):356-67.

Tejiokem MC, Gouandjika I, Béniguel L, Zanga MC, Tene G, Gody JC, Njamkepo E, Kfutwah A, Penda I, Bilong C, Rousset D, Pouillot R, Tangy F, Baril L. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. *PLoS ONE*. 2007 Dec 5;2(12):e1260.

Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. *Clin Infect Dis*. 2007 Sep 1;45(5):637-42

Moss WJ, Scott S, Mugala N, Ndhlovu Z, Beeler JA, Audet SA, Ngala M, Mwangala S, Nkonga-Mwangilwa C, Ryon JJ, Monze M, Kasolo F, Quinn TC, Cousens S, Griffin DE, Cutts FT. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. *J Infect Dis*. 2007 Aug 1;196(3):347-55.

Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. *Pediatrics*. 2006 Aug;118(2):e315-22.

Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. *Pediatrics*. 2003 Jun;111(6 Pt 1):e641-4.

Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G. MMR vaccine in HIV-infected children—potential hazards? *Vaccine*. 2001 Jul 16;19(28-29):3816-9.

Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. *Clin Infect Dis*. 2001 Apr 1;32(7):1090-4.

Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. *Clin Infect Dis*. 1999 Jul;29(1):106-12.

Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC. Secondary failure rates of measles vaccines: a metaanalysis of published studies. *Pediatr Infect Dis J.* 1996 Jan;15(1):62-6.

Breña AE, Cooper ER, Cabral HJ, Pelton SI. Antibody response to measles and rubella vaccine by children with HIV infection. *J Acquir Immune Defic Syndr.* 1993 Oct;6(10):1125-9.

Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, Mukamabano B, Van Goethem C, Van de Perre P. Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda. *Am J Dis Child.* 1992 May;146(5):550-5.

Safety

WHO: Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. *Wkly Epidemiol Rec.* 2009; 84, 325-332.

Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. *Vaccine.* 2009 May 5;27(20):2701-6.

Jefferson T, Price D, Demicheli V, Bianco E; European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. *Vaccine.* 2003 Sep 8;21(25-26):3954-60

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. *Pediatr Infect Dis J.* 2008 Aug;27(8):724-30.

Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. *Vaccine.* 2008 Apr 24;26(18):2234-41.

Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. *MMWR Morb Mortal Wkly Rep.* 2008 Mar 14;57(10):258-60.

France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Hohman K, Chen RT, Davis R; Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. *Pediatrics*. 2008 Mar;121(3):e687-92.

Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. *Infection*. 2007 Oct;35(5):326-33.

Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. *Pediatr Infect Dis J*. 2007 Feb;26(2):153-8.

WHO Immunization safety. Adverse events following immunization.
http://www.who.int/immunization_safety/publications/aefi/en/

Last update: 12 April 2006

Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. *Pediatr Infect Dis J*. 2005 Dec;24(12):1083-8.

De Stefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study metropolitan Atlanta. *Pediatrics* 2004;113:259-266.

Maher JE, Mullooly JP, Drew L, et al. Infant vaccinations and childhood asthma among full-term infants. *Pharmacoepidemiol Drug Saf* 2004;13:1-9.

McKeever TM, Lewis SA, Smith C, et al. Vaccination and allergic disease: a birth cohort study. *Am J Public Health* 2004;94:985-989.

Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA* 2004;292:351-357.

Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. *Am J Epidemiol* 2003;157:158-165.

Stück B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. *Asian Pac J Allergy Immunol.* 2002 Jun;20(2):113-20.

Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med* 2002;347:1477-1482.

Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ; Kaiser Permanente Medical Team for Varivax. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. *Pediatr Infect Dis J.* 2002 Jun;21(6):555-61.

Barlow WE, Davis RL, Glasser JW. The risk of seizures after receipt of whole cell pertussis or measles mumps and rubella vaccine. *N Engl J Med* 2001;345:656-661.

Carapetis JR, Curtis N. MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare. *BMJ.* 2001 October 13; 323(7317): 869.

Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. *Pediatrics* 2000;106:e62.

Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen year prospective follow up. *Pediatr Infect Dis J* 2000;19:1127-1134.

Duclos P, Ward BJ. Measles vaccines: a review of adverse events. *Drug Saf.* 1998 Dec;19(6):435-54.

Cost-effectiveness

Uzicanin A, Zhou F, Eggers R, Webb E, Strebel P. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa. *Vaccine.* 2004 Sep 3;22(25-26):3419-26.

Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, Zimmerman L, McCauley MM. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. *J Infect Dis.* 2004 May 1;189 Suppl 1:S131-45.

Dayan GH, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P. Cost-effectiveness of three different vaccination strategies against measles in Zambian children. *Vaccine.* 2004 Jan 2;22(3-4):475-84.

Beutels P, Gay NJ. Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country. *Epidemiol Infect.* 2003 Apr;130(2):273-83.

Acharya A, Diaz-Ortega JL, Tambini G, de Quadros C, Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. *Vaccine.* 2002 Sep 10;20(27-28):3332-41.

Zwanziger J, Szilagyi PG, Kaul P. Evaluating the benefits of increasing measles immunization rates. *Health Serv Res.* 2001 Oct;36(5):885-909.

Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. *Vaccine.* 1998 May-Jun;16(9-10):989-96.

Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ. Cost-effectiveness of measles outbreak intervention strategies. *Aust N Z J Public Health.* 1998 Feb;22(1):126-32.

Policy issues

John S, Sanghi S, Prasad S, Bose A, George K. Two doses of measles vaccine: are some states in India ready for it? *J Trop Pediatr.* 2009 Aug;55(4):253-6.

Wood JG, Gidding HF, Heywood A, Macartney K, McIntyre PB, Macintyre CR. Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia. *Vaccine.* 2009 Jan 7;27(2):313-8.

Centers for Disease Control and Prevention (CDC). Progress toward measles elimination—European Region, 2005--2008. *MMWR Morb Mortal Wkly Rep.* 2009 Feb 20;58(6):142-5.

Orenstein WA, Hinman AR, Strebel PJ. Measles: the need for 2 opportunities for prevention. *Clin Infect Dis.* 2006;42:320-321.

Centers for Disease Control and Prevention. Progress in reducing global measles deaths, 1999-2004. *MMWR Morb Mortal Wkly Rep.* 2006;55:247-249.

Parker AA, Staggs W, Dayan GH, Ortega-Sánchez IR, Rota PA, Lowe L, Boardman P, Teclaw R, Graves C, LeBaron CW. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. *N Engl J Med.* 2006 Aug 3;355(5):447-55.

King A, Varughese P, De Serres G, Tipples GA, Waters J; Working Group on Measles Elimination. Measles elimination in Canada. *J Infect Dis.* 2004 May 1;189 Suppl 1:S236-42.

De Quadros CA, Izurieta H, Carrasco P, Brana M, Tambini G. Progress toward measles eradication in the region of the Americas. *J Infect Dis.* 2003 May 15;187 Suppl 1:S102-10.

Pebody RG, Gay NJ, Hesketh LM; et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. *Vaccine.* 2002;20:1134-1140.

Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. *JAMA.* 1999 Jul 7;282(1):47-53.

Ratnam S, West R, Gadag V, Burris J. Measles immunization strategy: measles antibody response following MMR II vaccination of children at one year of age. *Can J Public Health.* 1996 Mar-Apr;87(2):97-100.

Yuan L. Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. *CMAJ.* 1994 Apr 1;150(7):1093-8.

Hutchins SS, Markowitz LE, Mead P, Mixon D, Sheline J, Greenberg N, Preblud SR, Orenstein WA, Hull HF. A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. *Am J Epidemiol.* 1990 Jul;132(1):157-68.